Pharma & Human Health

Da Volterra announces positive Phase 2 results for DAV132, the first product protecting against the clinical consequences of intestinal microbiota dysbiosis

Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota from the damaging effects of antibiotics, today announced positive top-line results from a Phase 2 clinical trial ‘SHIELD’ evaluatingDAV132 in patients […]